Skip to main content

TELA Bio, Inc 8-K, filed Nov 10, 2026

TELA Bio, Inc. (TELA)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

TELA Bio, Inc filed this 8-K on November 10, 2026.

TELA Bio reported third-quarter 2026 revenue of $19.0 million, down 8% from the prior-year period, while a $17.0 million cost-reduction initiative extends cash runway into 2028. Adjusted EBITDA loss improved 39% to $3.4 million, and cash totaled $22.7 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits